Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 41 entries
Sorted by: Best Match Show Resources per page
Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.

Clinical investigation

VanDevanter DR, Konstan MW.
PMID: 26146539
Clin Investig (Lond). 2012;2(2):163-175. doi: 10.4155/cli.11.174.

Cystic fibrosis (CF) is a complex genetic disease characterized by death from loss of lung function. Therapies target pathophysiologic changes associated with pulmonary disease progression. Although therapeutic mechanisms differ, efficacy demonstration is limited to a few accepted outcome measures,...

Cite
VanDevanter DR, Konstan MW. Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. Clin Investig (Lond). 2012;2(2):163-175doi: 10.4155/cli.11.174.
VanDevanter, D. R., & Konstan, M. W. (2012). Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. Clinical investigation, 2(2), 163-175. https://doi.org/10.4155/cli.11.174
VanDevanter, Donald R, and Konstan, Michael W. "Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease." Clinical investigation vol. 2,2 (2012): 163-175. doi: https://doi.org/10.4155/cli.11.174
VanDevanter DR, Konstan MW. Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. Clin Investig (Lond). 2012;2(2):163-175. doi: 10.4155/cli.11.174. PMID: 26146539; PMCID: PMC4486293.
Copy Download .nbib Format: NLM
The Essential Role of Educator Development: 10 Years of the ACC Emerging Faculty Program.

Journal of the American College of Cardiology

Auseon AJ, O'Gara PT, Klodas E, Holmes DR, Jackson MJ, Green JS, Konstam MA, Nishimura RA.
PMID: 27151350
J Am Coll Cardiol. 2016 May 10;67(18):2177-2182. doi: 10.1016/j.jacc.2016.02.052.

The American College of Cardiology Emerging Faculty program was developed in 2005 to promote a systematic approach to "educate the educators" through training and mentorship. A primary focus of the program is the biennial Teaching Skills Workshop, which has...

Cite
Auseon AJ, O'Gara PT, Klodas E, et al. The Essential Role of Educator Development: 10 Years of the ACC Emerging Faculty Program. J Am Coll Cardiol. 2016;67(18):2177-2182doi: 10.1016/j.jacc.2016.02.052.
Auseon, A. J., O'Gara, P. T., Klodas, E., Holmes, D. R., Jackson, M. J., Green, J. S., Konstam, M. A., & Nishimura, R. A. (2016). The Essential Role of Educator Development: 10 Years of the ACC Emerging Faculty Program. Journal of the American College of Cardiology, 67(18), 2177-2182. https://doi.org/10.1016/j.jacc.2016.02.052
Auseon, Alex J, et al. "The Essential Role of Educator Development: 10 Years of the ACC Emerging Faculty Program." Journal of the American College of Cardiology vol. 67,18 (2016): 2177-2182. doi: https://doi.org/10.1016/j.jacc.2016.02.052
Auseon AJ, O'Gara PT, Klodas E, Holmes DR, Jackson MJ, Green JS, Konstam MA, Nishimura RA. The Essential Role of Educator Development: 10 Years of the ACC Emerging Faculty Program. J Am Coll Cardiol. 2016 May 10;67(18):2177-2182. doi: 10.1016/j.jacc.2016.02.052. PMID: 27151350.
Copy Download .nbib Format: NLM
Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation.

Clinical and translational gastroenterology

Gelfond D, Heltshe S, Ma C, Rowe SM, Frederick C, Uluer A, Sicilian L, Konstan M, Tullis E, Roach RN, Griffin K, Joseloff E, Borowitz D.
PMID: 28300821
Clin Transl Gastroenterol. 2017 Mar 16;8(3):e81. doi: 10.1038/ctg.2017.10.

OBJECTIVES: A defect in bicarbonate secretion contributes to the pathophysiology of gastrointestinal complications in patients with cystic fibrosis (CF). We measured gastrointestinal pH, clinical outcomes, and intestinal transit profiles in patients with the G551D mutation before and after treatment...

Cite
Gelfond D, Heltshe S, Ma C, et al. Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation. Clin Transl Gastroenterol. 2017;8(3):e81doi: 10.1038/ctg.2017.10.
Gelfond, D., Heltshe, S., Ma, C., Rowe, S. M., Frederick, C., Uluer, A., Sicilian, L., Konstan, M., Tullis, E., Roach, R. N., Griffin, K., Joseloff, E., & Borowitz, D. (2017). Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation. Clinical and translational gastroenterology, 8(3), e81. https://doi.org/10.1038/ctg.2017.10
Gelfond, Daniel, et al. "Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation." Clinical and translational gastroenterology vol. 8,3 (2017): e81. doi: https://doi.org/10.1038/ctg.2017.10
Gelfond D, Heltshe S, Ma C, Rowe SM, Frederick C, Uluer A, Sicilian L, Konstan M, Tullis E, Roach RN, Griffin K, Joseloff E, Borowitz D. Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation. Clin Transl Gastroenterol. 2017 Mar 16;8(3):e81. doi: 10.1038/ctg.2017.10. PMID: 28300821; PMCID: PMC5387753.
Copy Download .nbib Format: NLM
Biodiversity hotspots revealed.

People & the planet

Mittermeier R, Bowles I, Konstant W.
PMID: 12348874
People Planet. 1998;7(4):10-5.

No abstract available.

Cite
Mittermeier R, Bowles I, Konstant W. Biodiversity hotspots revealed. People Planet. 1998;7(4):10-5
Mittermeier, R., Bowles, I., & Konstant, W. (1998). Biodiversity hotspots revealed. People & the planet, 7(4), 10-5.
Mittermeier, R, et al. "Biodiversity hotspots revealed." People & the planet vol. 7,4 (1998): 10-5.
Mittermeier R, Bowles I, Konstant W. Biodiversity hotspots revealed. People Planet. 1998;7(4):10-5. PMID: 12348874.
Copy Download .nbib Format: NLM
Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities.

Journal of clinical and translational science

Lanzkron S, Sawicki GS, Hassell KL, Konstan MW, Liem RI, McColley SA.
PMID: 30828476
J Clin Transl Sci. 2018 Oct;2(5):334-342. doi: 10.1017/cts.2018.338.

INTRODUCTION: A growing population of adults living with severe, chronic childhood-onset health conditions has created a need for specialized health care delivered by providers who have expertise both in adult medicine and in those conditions. Optimal care of these...

Cite
Lanzkron S, Sawicki GS, Hassell KL, et al. Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. J Clin Transl Sci. 2018;2(5):334-342doi: 10.1017/cts.2018.338.
Lanzkron, S., Sawicki, G. S., Hassell, K. L., Konstan, M. W., Liem, R. I., & McColley, S. A. (2018). Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. Journal of clinical and translational science, 2(5), 334-342. https://doi.org/10.1017/cts.2018.338
Lanzkron, Sophie, et al. "Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities." Journal of clinical and translational science vol. 2,5 (2018): 334-342. doi: https://doi.org/10.1017/cts.2018.338
Lanzkron S, Sawicki GS, Hassell KL, Konstan MW, Liem RI, McColley SA. Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. J Clin Transl Sci. 2018 Oct;2(5):334-342. doi: 10.1017/cts.2018.338. PMID: 30828476; PMCID: PMC6390387.
Copy Download .nbib Format: NLM
Cystic fibrosis.

American journal of respiratory and critical care medicine

Davis PB, Drumm M, Konstan MW.
PMID: 8912731
Am J Respir Crit Care Med. 1996 Nov;154(5):1229-56. doi: 10.1164/ajrccm.154.5.8912731.

No abstract available.

Cite
Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med. 1996;154(5):1229-56doi: 10.1164/ajrccm.154.5.8912731.
Davis, P. B., Drumm, M., & Konstan, M. W. (1996). Cystic fibrosis. American journal of respiratory and critical care medicine, 154(5), 1229-56. https://doi.org/10.1164/ajrccm.154.5.8912731
Davis, P B, et al. "Cystic fibrosis." American journal of respiratory and critical care medicine vol. 154,5 (1996): 1229-56. doi: https://doi.org/10.1164/ajrccm.154.5.8912731
Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med. 1996 Nov;154(5):1229-56. doi: 10.1164/ajrccm.154.5.8912731. PMID: 8912731.
Copy Download .nbib Format: NLM
Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Zemanick ET, Konstan MW, VanDevanter DR, Rowe SM, Clancy JP, Odem-Davis K, Skalland M, Mayer-Hamblett N.
PMID: 33573995
J Cyst Fibros. 2021 Nov;20(6):965-971. doi: 10.1016/j.jcf.2021.01.011. Epub 2021 Feb 08.

BACKGROUND: The Characterizing CFTR Modulated Changes in Sweat Chloride and their Association with Clinical Outcomes (CHEC-SC) study is a large epidemiologic study designed to determine the relationship between sweat chloride response and clinical outcomes in people with cystic fibrosis...

Cite
Zemanick ET, Konstan MW, VanDevanter DR, et al. Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. J Cyst Fibros. 2021;20(6):965-971doi: 10.1016/j.jcf.2021.01.011.
Zemanick, E. T., Konstan, M. W., VanDevanter, D. R., Rowe, S. M., Clancy, J. P., Odem-Davis, K., Skalland, M., & Mayer-Hamblett, N. (2021). Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 20(6), 965-971. https://doi.org/10.1016/j.jcf.2021.01.011
Zemanick, Edith T, et al. "Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study." Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society vol. 20,6 (2021): 965-971. doi: https://doi.org/10.1016/j.jcf.2021.01.011
Zemanick ET, Konstan MW, VanDevanter DR, Rowe SM, Clancy JP, Odem-Davis K, Skalland M, Mayer-Hamblett N. Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. J Cyst Fibros. 2021 Nov;20(6):965-971. doi: 10.1016/j.jcf.2021.01.011. Epub 2021 Feb 08. PMID: 33573995; PMCID: PMC8349375.
Copy Download .nbib Format: NLM
Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Bilton D, Fajac I, Pressler T, Clancy JP, Sands D, Minic P, Cipolli M, Galeva I, Solé A, Quittner AL, Jumadilova Z, Ciesielska M, Konstan MW.
PMID: 34144923
J Cyst Fibros. 2021 Nov;20(6):1010-1017. doi: 10.1016/j.jcf.2021.05.013. Epub 2021 Jun 16.

BACKGROUND: . In CLEAR-108-a phase 3, randomised, open-label study-once-daily amikacin liposome inhalation suspension (ALIS) was noninferior to twice-daily tobramycin inhalation solution (TIS) in improving lung function in patients with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa infection after 3...

Cite
Bilton D, Fajac I, Pressler T, et al. Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. J Cyst Fibros. 2021;20(6):1010-1017doi: 10.1016/j.jcf.2021.05.013.
Bilton, D., Fajac, I., Pressler, T., Clancy, J. P., Sands, D., Minic, P., Cipolli, M., Galeva, I., Solé, A., Quittner, A. L., Jumadilova, Z., Ciesielska, M., Konstan, M. W. (2021). Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 20(6), 1010-1017. https://doi.org/10.1016/j.jcf.2021.05.013
Bilton, Diana, et al. "Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection." Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society vol. 20,6 (2021): 1010-1017. doi: https://doi.org/10.1016/j.jcf.2021.05.013
Bilton D, Fajac I, Pressler T, Clancy JP, Sands D, Minic P, Cipolli M, Galeva I, Solé A, Quittner AL, Jumadilova Z, Ciesielska M, Konstan MW. Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. J Cyst Fibros. 2021 Nov;20(6):1010-1017. doi: 10.1016/j.jcf.2021.05.013. Epub 2021 Jun 16. PMID: 34144923.
Copy Download .nbib Format: NLM
Increasing life expectancy in cystic fibrosis: Advances and challenges.

Pediatric pulmonology

McBennett KA, Davis PB, Konstan MW.
PMID: 34672432
Pediatr Pulmonol. 2021 Oct 21; doi: 10.1002/ppul.25733. Epub 2021 Oct 21.

Since the first description of cystic fibrosis in 1938, there have been significant advances in both quality of life and longevity for people living with this disease. In this article we describe the milestones of the last 80 years...

Cite
McBennett KA, Davis PB, Konstan MW. Increasing life expectancy in cystic fibrosis: Advances and challenges. Pediatr Pulmonol. 2021;doi: 10.1002/ppul.25733.
McBennett, K. A., Davis, P. B., & Konstan, M. W. (2021). Increasing life expectancy in cystic fibrosis: Advances and challenges. Pediatric pulmonology, . https://doi.org/10.1002/ppul.25733
McBennett, Kimberly A, et al. "Increasing life expectancy in cystic fibrosis: Advances and challenges." Pediatric pulmonology vol. (2021). doi: https://doi.org/10.1002/ppul.25733
McBennett KA, Davis PB, Konstan MW. Increasing life expectancy in cystic fibrosis: Advances and challenges. Pediatr Pulmonol. 2021 Oct 21; doi: 10.1002/ppul.25733. Epub 2021 Oct 21. PMID: 34672432.
Copy Download .nbib Format: NLM
Association of Volume Overload With Kidney Function Outcomes Among Patients With Heart Failure With Reduced Ejection Fraction.

Kidney international reports

McCallum W, Tighiouart H, Testani JM, Griffin M, Konstam MA, Udelson JE, Sarnak MJ.
PMID: 33102958
Kidney Int Rep. 2020 Jul 23;5(10):1661-1669. doi: 10.1016/j.ekir.2020.07.015. eCollection 2020 Oct.

INTRODUCTION: In patients with heart failure with reduced ejection fraction (HFrEF), volume overload is associated with mortality. Few studies that have examined the relation between volume and long-term kidney function outcomes in HFrEF.METHODS: Using data from the Efficacy of...

Cite
McCallum W, Tighiouart H, Testani JM, et al. Association of Volume Overload With Kidney Function Outcomes Among Patients With Heart Failure With Reduced Ejection Fraction. Kidney Int Rep. 2020;5(10):1661-1669doi: 10.1016/j.ekir.2020.07.015.
McCallum, W., Tighiouart, H., Testani, J. M., Griffin, M., Konstam, M. A., Udelson, J. E., & Sarnak, M. J. (2020). Association of Volume Overload With Kidney Function Outcomes Among Patients With Heart Failure With Reduced Ejection Fraction. Kidney international reports, 5(10), 1661-1669. https://doi.org/10.1016/j.ekir.2020.07.015
McCallum, Wendy, et al. "Association of Volume Overload With Kidney Function Outcomes Among Patients With Heart Failure With Reduced Ejection Fraction." Kidney international reports vol. 5,10 (2020): 1661-1669. doi: https://doi.org/10.1016/j.ekir.2020.07.015
McCallum W, Tighiouart H, Testani JM, Griffin M, Konstam MA, Udelson JE, Sarnak MJ. Association of Volume Overload With Kidney Function Outcomes Among Patients With Heart Failure With Reduced Ejection Fraction. Kidney Int Rep. 2020 Jul 23;5(10):1661-1669. doi: 10.1016/j.ekir.2020.07.015. eCollection 2020 Oct. PMID: 33102958; PMCID: PMC7569703.
Copy Download .nbib Format: NLM
What Is Cystic Fibrosis?.

JAMA

Endres TM, Konstan MW.
PMID: 35015036
JAMA. 2022 Jan 11;327(2):191. doi: 10.1001/jama.2021.23280.

No abstract available.

Cite
Endres TM, Konstan MW. What Is Cystic Fibrosis?. JAMA. 2022;327(2):191doi: 10.1001/jama.2021.23280.
Endres, T. M., & Konstan, M. W. (2022). What Is Cystic Fibrosis?. JAMA, 327(2), 191. https://doi.org/10.1001/jama.2021.23280
Endres, Tori M, and Konstan, Michael W. "What Is Cystic Fibrosis?." JAMA vol. 327,2 (2022): 191. doi: https://doi.org/10.1001/jama.2021.23280
Endres TM, Konstan MW. What Is Cystic Fibrosis?. JAMA. 2022 Jan 11;327(2):191. doi: 10.1001/jama.2021.23280. PMID: 35015036.
Copy Download .nbib Format: NLM
Opportunities for life course research through the integration of data across Clinical and Translational Research Institutes.

Journal of clinical and translational science

Hanson HA, Hay WW, Tobin JN, Barkin SL, Atkins M, Karagas MR, Dozier AM, Wetmore C, Konstan MW, Heubi JE.
PMID: 30370067
J Clin Transl Sci. 2018 Jun;2(3):156-162. doi: 10.1017/cts.2018.29.

INTRODUCTION: Early life exposures affect health and disease across the life course and potentially across multiple generations. The Clinical and Translational Research Institutes (CTSIs) offer an opportunity to utilize and link existing databases to conduct lifespan research.METHODS: A survey...

Cite
Hanson HA, Hay WW, Tobin JN, et al. Opportunities for life course research through the integration of data across Clinical and Translational Research Institutes. J Clin Transl Sci. 2018;2(3):156-162doi: 10.1017/cts.2018.29.
Hanson, H. A., Hay, W. W., Tobin, J. N., Barkin, S. L., Atkins, M., Karagas, M. R., Dozier, A. M., Wetmore, C., Konstan, M. W., & Heubi, J. E. (2018). Opportunities for life course research through the integration of data across Clinical and Translational Research Institutes. Journal of clinical and translational science, 2(3), 156-162. https://doi.org/10.1017/cts.2018.29
Hanson, Heidi A, et al. "Opportunities for life course research through the integration of data across Clinical and Translational Research Institutes." Journal of clinical and translational science vol. 2,3 (2018): 156-162. doi: https://doi.org/10.1017/cts.2018.29
Hanson HA, Hay WW, Tobin JN, Barkin SL, Atkins M, Karagas MR, Dozier AM, Wetmore C, Konstan MW, Heubi JE. Opportunities for life course research through the integration of data across Clinical and Translational Research Institutes. J Clin Transl Sci. 2018 Jun;2(3):156-162. doi: 10.1017/cts.2018.29. PMID: 30370067; PMCID: PMC6202009.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 41 entries